Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Previous studies addressing preoperative somatostatin analogs (SSA) treatment and subsequent
surgical cure rates are conflicting, reporting a benefit, or no difference between groups.
And most reported studies were rather small and were made in retrospect, we conducted a
prospective, randomized study to investigate whether 4-month preoperative lanreotide
treatment would improve the surgical cure rate of newly diagnosed acromegalic patients with
macroadenomas. The investigators also aimed to investigate whether there were differences in
the incidence of surgical complications, and duration of neurosurgical hospital stay.